Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $6.47 million versus the consensus estimate of $16.28 million.

Reiterate 2026 guidance of <$390 million operational cash burn, supporting runway into early 2028 without additional financing

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.